CompletedNCT05530577
Semaglutide effects on nicotine use and smoking lapses
About this title
Read the official source — NCT05530577Medication studyAges 21–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 21 years to 65 years.
- Listed locations
- Chapel HillSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 7, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT05530577
- Official title
Show the full official title
Effects of Semaglutide on Nicotine Intake and Smoking Lapse
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chapel Hill
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of North Carolina, Chapel Hill, a university.
Did this study involve medication?
Yes. The study involved medication, including Semaglutide and Sham/placebo.
Who was this study for?
Listed age limits: 21 years to 65 years.
